Obesity Management

Data from SURMOUNT-2 presented at ADA 2023 build on results from the SURMOUNT-1 trial, with results detailing the weight loss achieved with tirzepatide in people with type 2 diabetes and overweight or obesity.

A pair of phase 2 trials presented at ADA 2023 detail the body weight lowering and glycemic control benefits of orforglipron, an oral GLP-1 RA developed by Eli Lilly and Company.

Data from a phase 2 dose-finding trial from ADA 2023 suggests use of survodutide was associated with a mean body weight reduction of 14.9% at 46 weeks, with 67% of people using survodutide 4.8 mg losing 15% or more of their baseline body weight.

To celebrate the 10-year anniversary of the AMA recognizing obesity as a disease, this feature leverages the perspective of key opinion leaders to examine what has changed and what has not since the AMA's declaration in June 2013.

A matched case-control study of nearly 100 women details the reduced effect of anti-obesity medications in those with a history of breast cancer and aromatase inhibitor use.

Based on the results of 2 studies, lower birthweight was associated with younger age, lower prevalence of obesity, and fewer individuals with a family history of T2D.

Research presented at ENDO 2023 suggests a high number of adults in the United States with normal BMI still have obesity.

A prospective, nonrandomized trial has returned results indicating adolescents and young adults who undergo bariatric surgery experienced a decrease in bone density relative to their counterparts who opted for exercise and nutrition counseling.

Data from the COVID-OUT trial suggests use of metformin could reduce a person's risk of developing long COVID by more than 50% relative to placebo therapy, with results also providing insight into the apparent lack of benefit with ivermectin and fluvoxamine.

An analysis of nationwide data in Singapore suggests obesity is set to become the leading metabolic risk factor underlying acute myocardial infarction onset, overtaking hypertension and hyperlipidemia in the coming decades.

The ongoing shortage of GLP-1 receptor agonists, namely semaglutide, has prompted the US Food and Drug Administration to issue a warning to patients and providers related to use of compounded semaglutide.

The changes in sleep quality were notably associated with a higher prevalence of obesity indicators in men following the COVID-19 outbreak.

An analysis of data from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program provides an overview of changing rates of access and utilization of metabolic and bariatric surgery among US youths.

Clinical trial data suggest overweight and obese patients with atrial fibrillation who lose weight prior to a catheter ablation procedure experience better clinical outcomes.

Phase 2 data suggest the oral small-molecule GLP-1R agonist reduced HbA1c at all dose levels studied and reduced body weight at doses of ≥80 mg twice daily compared with placebo in adults with T2D.

A new analysis found differences in the gut bacteria seen in adults with obesity, suggesting that changes in the gut microbiota that predispose to adult obesity may begin in early childhood.

Despite stable rates of heavy alcohol use, deaths from alcohol-associated liver damage have risen in the US. A new study suggests an increase in the damaging effects of alcohol use in people with metabolic syndrome could be driving this apparent increase.

Announced on May 10, 2023, topline results of the phase 2 dose-finding trial for BI 456906 suggests use was associated with reductions in body weight of up to 14.9% during the 46-week study.

Patients with psoriatic arthritis and/or psoriasis reported improved BMI and HbA1C after 6 months of apremilast—with pronounced benefit among patients with obesity.

Data indicate higher BMI is associated with an increased risk of severe respiratory disease, including COVID-19, with the highest risk observed in those with a BMI in the range of 35-60.

Data from the SURMOUNT-2 trial demonstrate use of tirzepatide 10 mg and 15 mg were associated with mean weight reductions of 13.4% and 15.7%, respectively, with more than 80% of tirzepatide users achieving a body weight reduction of 5% or greater.

Data from the BRAVES trial indicates 70% of patients undergoing metabolic or bariatric surgery with histologically confirmed NASH achieved resolution at 52 weeks.

There were significant positive associations found of overweight, obesity, and a 5-unit increase in BMI with colorectal cancer risk when using BMI measured 8-10 years prior to diagnosis.

Most associate bariatric surgery with improved health outcomes, but a new study suggests clinicians and patients should be aware of potential changes in bone density brought on as a result of undergoing bariatric surgery.

Many effective anti-obesity medications could be manufactured and sold profitably for a low price, with estimated minimum prices up to 20-fold cheaper than current prices in some countries.

A new study leveraging data from 184 countries based on 11 dietary factors provides an overview of the diet attributable burden of type 2 diabetes in the world today.

A prospective study of more than 120 patients who underwent bariatric surgery sheds additional light on the potential benefits incurred by undergoing weight loss surgery in people with obesity.

A retrospective, propensity score-matched analysis details significant risk reductions achieved with bariatric surgery in patients with nonalcoholic fatty liver disease and obesity.

Children exposed to maternal COVID-19 during pregnancy showed lower birth weight, lower birth BMI, and accelerated postnatal weight gain, compared with those unexposed.

A systematic review and meta-analysis of more than 120 randomized trials offers new insight into the effects of weight regain on cardiometabolic risk up to 5 years after the cessation of a behavioral management program.